Evidence map›Paper›PMID 34522428›Full record

ArticleSouthern African journal of HIV medicine2021

Establishing targets for advanced HIV disease: A call to action.

David B Meya, Lillian Tugume, Vennie Nabitaka, Proscovia Namuwenge, Sam Phiri, Rita Oladele, Bilkisu Jibrin, Mojisola Mobolaji-Bello, Cecilia Kanyama, Werner Maokola and 11 more

Open access · goldAbstract read
In one paragraph

Article in Southern African journal of HIV medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 7 countries.

David B MeyaDepartment of Research, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID https://orcid.org/0000-0002-8854-0321
Lillian TugumeDepartment of Research, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID https://orcid.org/0000-0002-1293-1545
Vennie NabitakaHIV Department, Clinton Health Access Initiative, Kampala, Uganda.ORCID https://orcid.org/0000-0001-6161-7555
Proscovia NamuwengeDepartment of HIV Care and Treatment, Ministry of Health, Uganda, Kampala, Uganda.ORCID https://orcid.org/0000-0002-4794-7918
Sam PhiriHIV Department, Lighthouse Trust Malawi, Lilongwe, Malawi.ORCID https://orcid.org/0000-0002-9372-212X
Rita OladeleCollege of Medicine University of Lagos, Lagos, Nigeria.ORCID https://orcid.org/0000-0003-1488-3345
Bilkisu JibrinDepartment of HIV Care, Treatment and Support, Ministry of Health, Lagos, Nigeria.ORCID https://orcid.org/0000-0003-1943-2893
Mojisola Mobolaji-BelloDepartment of HIV Care, Treatment and Support, Ministry of Health, Lagos, Nigeria.ORCID https://orcid.org/0000-0003-4784-9725
Cecilia KanyamaDepartment of Medicine, University of North Carolina Project-Malawi, Kamuzu Central Hospital, Lilongwe, Malawi.ORCID https://orcid.org/0000-0001-8673-3763
Werner MaokolaNational AIDS Control Program, Ministry of Health, Tanzania, Dar-es-Saalam, Tanzania.ORCID https://orcid.org/0000-0003-0782-0784
Sayoki MfinangaDepartment of Research, Muhimbili Medical Research Centre, Dar-es-Salaam, Tanzania.ORCID https://orcid.org/0000-0001-9067-2684
Cordelia KatureebeDepartment of National HIV Care and Treatment, Ministry of Health, Kampala, Uganda.ORCID https://orcid.org/0000-0003-0184-5753
Ikechukwu AmamiloGlobal Health Access Program, Clinton Health Access Initiative, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-3099-6147
Brian NgwatuHIV Program, Clinton Health Access Initiative, Kampala, Uganda.ORCID https://orcid.org/0000-0002-5612-4462
Joseph N JarvisDepartment of HIV, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0003-1459-5554
Thomas S HarrisonCentre for Global Health, Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.ORCID https://orcid.org/0000-0003-3619-4348
Amir ShroufiDepartment of HIV, Centres for Disease Control Foundation, Atlanta, United States of America.ORCID https://orcid.org/0000-0002-7850-2970
Radha RajasinghamDepartment of Medicine and International Health, University of Minnesota, Minneapolis, United States of America.ORCID https://orcid.org/0000-0001-5531-0231
David BoulwareDepartment of Medicine and International Health, University of Minnesota, Minneapolis, United States of America.ORCID https://orcid.org/0000-0002-4715-0060
Nelesh P GovenderDepartment of Research, National Institute for Communicable Diseases, Johannesburg, South Africa.ORCID https://orcid.org/0000-0001-7869-9462
Angela LoyseDepartment of Research, Centre for Global Health, Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.ORCID https://orcid.org/0000-0001-7853-1344
Clinton Health Access Initiative · USUniversity of Minnesota · USFederal Ministry of Health · NGMinistry of Health · UGSt George's, University of London · GBInfectious Diseases Institute · UGKamuzu Central Hospital · MWLighthouse Trust · MWMinistry of Health and Social Welfare · TZNational Health Laboratory Service · ZAUniversity of Lagos · NGUniversity of London · GB

Funding

Operational Research for Cryptococcal Antigen Screening (ORCAS) of HIV PatientsU01AI125003 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2016 to 2020
$3.4M
Phased Implementation of a Public Health Programme: Cryptococcal Screening and Treatment in South AfricaR01AI118511 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, GOVENDER, NELESH PREMAPRAGASAN · 2016 to 2020
$2.9M
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive personsK23AI138851 · NIAID · UNIVERSITY OF MINNESOTA · PI RAJASINGHAM, RADHA · 2018 to 2022
$954k
Medical Research Council MC_PC_MR/P006922/1NIAID NIH HHS K23 AI138851NIAID NIH HHS R01 AI118511NIAID NIH HHS U01 AI125003
6 · The paper itself

Abstract

The World Health Organization (WHO) has published a guideline for the management of individuals with advanced HIV disease (AHD) to reduce HIV-related deaths. The guideline consists of a package of recommendations including interventions to prevent, diagnose and treat common opportunistic infections, including tuberculosis (TB), cryptococcosis and severe bacterial infections, along with rapid initiation of antiretroviral treatment and enhanced adherence support. Currently no clear targets exist for these key interventions. Emerging programmatic data from Uganda, Tanzania and Nigeria suggest that an estimated 80% of eligible people continue to miss the recommended cryptococcal or TB testing, highlighting the remaining challenges to the effective implementation of WHO-recommended AHD packages of care in real-world resource-limited settings. The absence of mortality indicators for the leading causes of HIV-related deaths, because of the lack of mechanisms to ascertain cause of death, has had a negative impact on establishing interventions to reduce mortality. We suggest that setting 95-95-95 targets for CD4 testing, cryptococcal antigen and TB testing, and treatment that are aligned to the WHO AHD package of care would be a step in the right direction to achieving the greater goal of the WHO End TB strategy and the proposed new strategy to end cryptococcal meningitis deaths. However, these targets will only be achieved if there is healthcare worker training, expanded access to bedside point-of-care diagnostics for hospitalised patients and those in outpatient care who meet the criteria for AHD, and health systems strengthening to minimise delays in initiating the WHO-recommended therapies for TB and cryptococcal disease.

Indexed as

advanced HIV diseasecryptococcal antigentargetsTB-LAMtuberculosis

Identifiers

PMID34522428
PMCPMC8424734
OpenAlexW3191128604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.